Table 1.
Demographic and baseline characteristics comparison.
| Characteristics | Tirofiban (n = 98) | Control (n = 98) | P |
|---|---|---|---|
| Age (y) | 64.0 ± 11.4 | 64.8 ± 11.0 | 0.598 |
| Gender (male, %) | 84.7% | 78.5% | 0.268 |
| BMI (%) | 24.4 ± 3.6 | 24.9 ± 3.6 | 0.310 |
| HTN (%) | 57.1% | 70.4% | 0.053 |
| DM (%) | 29.6% | 39.8% | 0.175 |
| Hyperlipidemia (%) | 10.2% | 7.1% | 0.446 |
| Smoking (%) | 51.0% | 47.9% | 0.668 |
| Alcohol (%) | 20.4% | 19.4% | 0.718 |
| ALT (IU/L) | 47.6 ± 42.1 | 41.7 ± 52.8 | 0.398 |
| eGFR (ml/min·1.73 m2) | 82.6 ± 19.2 | 86.2 ± 21.4 | 0.219 |
| cTnT (μg/L) | 12.5 ± 6.1 | 12.4 ± 3.2 | 0.249 |
| CK-MB (U/L) | 148.3 ± 139.5 | 145.1 ± 95.1 | 0.849 |
| Concomitant drug | |||
| Aspirin (%) | 92.8% | 95.9% | 0.551 |
| Clopidogrel (%) | 70.4% | 81.6% | 0.066 |
| Ticagrelor (%) | 28.5% | 18.3% | 0.092 |
| Statins (%) | 100% | 100% | 1.000 |
| ACEI/ARB (%) | 88.7% | 79.6% | 0.078 |
| β-Blocker (%) | 93.8% | 89.8% | 0.408 |
| PPI (%) | 87.7% | 90.8% | 0.488 |
BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; cTnT, cardiac troponin T; CK-MB, creatine kinase–MB; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; PPI, proton-pump inhibitors.